Growth hormone treatment in Noonan syndrome: The National Cooperative Growth Study experience☆,☆☆,★,★★,♢
Section snippets
Subjects
The methods of subject enrollment and data collection have been previously described.14 The NCGS includes 150 prepubertal and pubertal children (97 boys) with NS who had not been treated with GH before enrollment (data collection: June 1986 through February 1995). The diagnosis of NS was made by the treating physician. The enrollment forms included reports of congenital heart disease in 42% of these children and dysmorphic features in 76% of them. Relevant concomitant medications were
RESULTS
The mean height SDS at enrollment was -3.5 standardized to normal growth data from the National Center for Health Statistics15 and -1.35 standardized to the NS growth data of Ranke et al.6 The stimulated peak GH levels were less than 10 μg/L in 45% of the children, but their response to GH therapy was no different from that in children with stimulated peak GH levels greater than 10 μg/L.
Baseline characteristics of patients with NS, IGHD, and TS are shown in Table I. The ages at enrollment were
DISCUSSION
The patients with NS in the NCGS were short even by NS standards, because their height SDS was -1.35 according to the NS growth curves. As a group they were older and shorter and had a greater BA deficit than children in the NCGS with IGHD. Forty-two percent of these patients were reported to have congenital heart disease. In light of the known prevalence of cardiac lesions in NS, this occurrence represents a selection bias or was underreported. Among all the patients with NS in the NCGS, no
References (16)
- et al.
Growth hormone treatment in the United States: demographic and diagnostic features of 2331 children
J Pediatr
(1990) - et al.
Physical growth: National Center for Health Statistics percentiles
J Clin Endocrinol Metab
(1979) - et al.
Noonan syndrome: the changing phenotype
Am J Med Genet
(1985) - et al.
Associated noncardiac malformations in children with congenital heart disease
J Pediatr
(1963) Hypertelorism with Turner phenotype
Am J Dis Child
(1968)- et al.
The Ullrich-Noonan syndrome (Turner phenotype)
Am J Dis Child
(1974) - et al.
Noonan syndrome: a review
Am J Med Genet
(1985) - et al.
Noonan syndrome: growth and clinical manifestations in 144 cases
Eur J Pediatr
(1988)
Cited by (75)
Efficacy and safety of growth hormone therapy in children with Noonan syndrome
2023, Growth Hormone and IGF ResearchGonadal function in Noonan syndrome
2022, Annales d'EndocrinologieCitation Excerpt :Puberty is usually delayed of about two years for both gender in NS in comparison with the general population. In NS girls, the mean age at pubertal onset is between 13 and 14 years [5,6] and the mean age at menarche is around 14.5 years [7,8]. In NS boys, the mean age at pubertal onset is between 13.5 and 14.5 years [6,8–11] and men report first shave at a mean age of 17 years [7].
Management of growth failure and other endocrine aspects in patients with Noonan syndrome across Europe: A sub-analysis of a European clinical practice survey
2022, European Journal of Medical GeneticsCitation Excerpt :In view of the mechanisms underlying short stature in patients with NS, the usefulness of GH stimulation tests is disputable. Indeed, while there have been reports on GHD (Cotterill et al., 1996; Romano et al., 1996) or neurosecretory dysfunction (Ahmed et al., 1991; Noordam et al., 2001b; Tanaka et al., 1992), patients with NS (notably those with PTPN11 mutations) usually display normal or slightly increased GH levels associated with low serum IGF1 levels, suggesting GH insensitivity (Binder et al., 2005; Limal et al., 2006). GH insensitivity, as well as abnormal chondrocyte differentiation, both involving hyperactivation of the RAS/MAPK signalling pathway, were confirmed in vivo in transgenic mice expressing a NS-associated Ptpn11 allele (De Rocca Serra-Nedelec et al., 2012; Tajan et al., 2018).
Foreword
2019, Noonan Syndrome: Characteristics and InterventionsForeword
2019, Noonan Syndrome: Characteristics and InterventionsCardiac manifestations in noonan syndrome: Effects of growth hormone therapy
2019, Noonan Syndrome: Characteristics and Interventions
- ☆
From the Department of Pediatrics, New York Medical College, Valhalla, the Department of Pediatrics, State University of New York at Stony Brook, and the Department of Medical Affairs, Genentech, Inc., South San Francisco, California
- ☆☆
aSandra L. Blethen, MD, is a principal investigator on research contracts for Genentech, Inc., and is an advisor to the National Cooperative Growth Study.
- ★
bKen Dana is employed by Genentech, Inc.
- ★★
Reprint requests: Alicia A. Romano, MD, Department of Pediatrics, New York Medical College, Valhalla, NY 10595.
- ♢
0022-3476/96/$5.00 + 0 9/0/72347